FDA approves oral semaglutide for weight management

The US Food and Drug Administration (FDA) has approved Novo Nordisk's oral semaglutide formulation, marketed as Wegovy (oral), for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. This is the first oral GLP-1 receptor agonist licensed for weight management, offering a non-injectable alternative to the existing subcutaneous Wegovy, Ozempic, and tirzepatide (Mounjaro/Zepbound) formulations. [1]

Clinical basis for approval

The approval was supported by a clinical development programme evaluating oral semaglutide at therapeutic doses for weight management. Oral semaglutide had previously been approved at a lower dose as Rybelsus for type 2 diabetes. The weight-management formulation delivers a higher dose of semaglutide in an oral tablet, using the absorption enhancer SNAC (salcaprozate sodium) to facilitate gastric absorption of the peptide.

The OASIS and PIONEER clinical trial programmes demonstrated that oral semaglutide produces clinically meaningful weight loss, though the magnitude is generally lower than that achieved with injectable semaglutide at current therapeutic doses. Novo Nordisk has reported weight loss of approximately 15% in Phase 3 trials of the oral weight-management formulation. [1][2]

Significance for peptide therapeutics

The approval underscores a broader industry trend toward oral peptide formulations. Peptides have historically required injection because they are degraded in the gastrointestinal tract and poorly absorbed. The SNAC absorption-enhancement technology used in oral semaglutide represents one of the first commercially successful approaches to oral peptide delivery.

This approval follows the FDA's earlier 2025 approval of orforglipron (Foundayo), the first fully oral small-molecule GLP-1 receptor agonist for obesity. Unlike orforglipron, which is a non-peptide oral GLP-1 agonist, the Wegovy pill is the peptide semaglutide itself formulated for oral absorption — a distinction that matters for researchers studying peptide drug delivery technologies. [3]

UK regulatory status

At the time of writing, the oral semaglutide weight-management formulation has not yet received MHRA approval for the UK market. Injectable semaglutide (Wegovy) is already licensed in the UK for weight management and was recommended by NICE for NHS use. Injectable Ozempic is licensed for type 2 diabetes. The lower-dose oral semaglutide (Rybelsus) is licensed in the UK for type 2 diabetes.

Semaglutide in all formulations is a prescription-only medicine (POM) in the UK under MHRA regulation. Research-grade semaglutide is legal for research purposes but is not licensed for human consumption outside approved medicinal products. [4]

What this means for researchers

For peptide researchers, the oral semaglutide approval highlights several developments worth monitoring:

  • Oral peptide delivery platforms: SNAC and related absorption-enhancement technologies are expanding the range of peptides that can be delivered orally, potentially applicable beyond GLP-1 agonists.
  • Dose–response considerations: Oral semaglutide achieves lower bioavailability than injectable forms, and the clinical programme reflects this with different dosing strategies.
  • Competitive landscape: With both oral peptide semaglutide and oral non-peptide orforglipron now approved, the oral GLP-1 market is becoming increasingly competitive, with implications for pricing, access, and research funding priorities.

This article is for research and educational purposes only and does not constitute medical advice.

References

[1] Novo Nordisk. FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults. PR Newswire, 2025. Available at: https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html

[2] Novo Nordisk. OASIS 1: Semaglutide oral in obesity. Clinical trial programme, 2024–2025.

[3] Peptide Data. FDA approves orforglipron (Foundayo): first oral GLP-1 agonist for obesity marks shift in peptide therapeutics. 2025.

[4] MHRA. Semaglutide: prescription-only medicine status and UK regulatory framework. Medicines and Healthcare products Regulatory Agency.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.